



Francesco Negro

Contact

Francesco Negro

Publications (26)

Radu P, Becchetti C, Schropp J, Schmid P, Künzler-Heule P, Mertens J, Moradpour D, Mullhaupt B, Semela D, Negro F, Heim M, Clerc O, Roelens M, Keiser O, Berzigotti A, Swiss Hepatitis C Cohort Study. Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection. *Cancers (Basel)* 2024; 16

Moschouri E, Saleme G, Baserga A, Cerny A, Deibel A, Muellhaupt B, Meier M, Bernsmeier C, Ongaro M, Negro F, Grosjean M, Clerc O, Künzler-Heule P, Semela D, Hobi G, Stickel F, Mathieu A, Mdawar-Bailly E, Faouzi M, Moradpour D, Fraga M. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis. *Swiss Med Wkly* 2024; 154:3698.

Negro F, Muellhaupt B, Semela D, Blach S, Bruggmann P, De Gottardi A, Dufour J, Fraga M, Galante A, Razavi H, Vieira Barbosa J, Razavi-Shearer D. The current and future burden of hepatitis B in Switzerland: a modelling study. *Swiss Med Wkly* 2023; 153:40086.

Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batänjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. *Liver Int* 2021

Bobzin C, Semmo N, Semela D, Scheidegger C, Rauch A, Negro F, Moradpour D, Mäschi B, Lavanchy D, Künzler-Heule P, Keiser O, Fraga Christinet M, Cerny A, Bruggmann P, Bösiger C, Thurnheer M. Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. *Swiss Medical Forum* 2021; 21:184-186.

Mullhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. *Swiss Med Wkly* 2021; 151:w20399.

Roelens M, Keiser O, Negro F, Junker C, Semela D, Clerc O, Mullhaupt B, Schmid P, Semmo N, Cerny A, Moradpour D, Bertisch B, Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis* 2020; 7:ofaa308.

Goossens N, Semela D, Razavi H, Negro F, Muellhaupt B, Moriggia A, Mertens J, Jornayvaz F, Dufour J, Cerny A, Bellentani S, Estes C. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. *Swiss Med Wkly* 2019; 149:w20152.

Brezzi M, Keiser O, Negro F, Semela D, Mullhaupt B, Semmo N, Terziroli Beretta-Piccoli B, Moradpour D, Roelens M, Bertisch B, Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. *PloS one* 2019; 14:e0218706.

Bertisch B, Keiser O, Moradpour D, Zehnder C, Marinucci F, Roelens M, Moriggia A, Clerc O, Giudici F, Schmid P, Künzler-Heule P, Ottiger C, Mullhaupt B, Negro F, Brezzi M, Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?. *Clin Infect Dis* 2019

Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Mullhaupt B, Negro F, Semela D. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. *Swiss Med Wkly* 2019; 149:w14694.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. *PloS one* 2018; 13:e0209374.

Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017; 37:1431-1445.

Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Mullhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. *Swiss Med Wkly* 2015; 145:w14221.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Corrigendum: reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2015; 6:7280.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. *PloS one* 2015; 10:e0125214.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2014; 5:5699.

Lange C, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinverni R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PloS one* 2013; 8:e64053.

Lange C, Bochud P, Kutalik Z, Moradpour D, Semela D, Negro F, Mullhaupt B, Malinverni R, Kaiser L, Heim M, Cerny A, Cellerai C, Dufour J, Bibert S, Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol* 2013; 59:504-9.

Kuske L, Dufour J, Cerny A, Malinverni R, Heim M, Malé P, Moradpour D, Semela D, Negro F, Mullhaupt B, Mensen A, Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly* 2012; 142:w13651.

Patin E, Stewart G, Booth D, George J, Casanova J, Bréchet C, Rice C, Talal A, Jacobson I, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud P, Abel L, Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, Suppiah V, Martinetti G, Hirsch H, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour J, Heim M, Moradpour D, Cerny A, Malinverni R, French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012; 143:1244-52.e1-12.

Gonvers J, Troillet N, Negro F, Monnat M, Malinverni R, Dutoit V, Dufour F, Chuard C, Chave J, Cerny A, Borovicka J, Bernasconi E, Genné D, Mullhaupt B, Cavassini M, Heim M, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. *Swiss Med Wkly* 2010; 140:w13055.

Rauch A, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010; 138:1338-45, 1345.e1-7.

Bochud P, Negro F, Francioli P, Malinverni R, Cerny A, Moradpour D, Heim M, Borovicka J, Mullhaupt B, Dufour J, Bochud M, Overbeck K, Cai T, Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of hepatology 2009; 51:655-66.

Bernsmeier C, Duong F, Christen V, Pugnale P, Negro F, Terracciano L, Heim M. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008; 49:429-40.

Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of hepatology 2005; 42:323-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch